Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Cash: 2012-2024

Historic Change in Cash for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $196.1 million.

  • Ocular Therapeutix's Change in Cash fell 42.78% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 126.05%. This contributed to the annual value of $196.1 million for FY2024, which is 109.77% up from last year.
  • Per Ocular Therapeutix's latest filing, its Change in Cash stood at $196.1 million for FY2024, which was up 109.77% from $93.5 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Change in Cash peaked at $196.1 million during FY2024, and registered a low of -$63.9 million during FY2021.
  • Over the past 3 years, Ocular Therapeutix's median Change in Cash value was $93.5 million (recorded in 2023), while the average stood at $75.9 million.
  • In the last 5 years, Ocular Therapeutix's Change in Cash spiked by 3,979.78% in 2020 and then slumped by 136.80% in 2021.
  • Over the past 5 years, Ocular Therapeutix's Change in Cash (Yearly) stood at $173.6 million in 2020, then crashed by 136.80% to -$63.9 million in 2021, then increased by 3.18% to -$61.9 million in 2022, then skyrocketed by 251.15% to $93.5 million in 2023, then soared by 109.77% to $196.1 million in 2024.